A non-DRE, voided urine, genomic assay to diagnose prostate cancer and to assess its aggressiveness.
Comparing NCCN-based risk groups to the PROTEUS definition of high-risk localized prostate cancer to inform peri-operative care.
Prognostic impact of BRCA mutation on metastasis-free survival in a localized/locoregional high-risk real-world prostate cancer population. The silent burden: A SEER-based analysis of potential years ...
Dear Dr. Roach: I am a 53-year-old healthy male, and I always request to check my PSA levels each year. My 57-year-old brother's new doctor denied his request for a routine PSA check on their initial ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results